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Azoles inhibit ergosterol biosynthesis, 
resulting in ergosterol depletion and 
accumulation of toxic 14Į-methylated sterols 
in membranes of susceptible yeasts. We 
previously demonstrated that miconazole 
induces actin cytoskeleton stabilization in 
Saccharomyces cerevisiae prior to induction of 
reactive oxygen species (ROS), pointing to an 
ancillary mode of action. Using a genome-
wide agar-based screening, we demonstrate in 
this study that S. cerevisiae mutants affected 
in sphingolipid and ergosterol biosynthesis, 
namely ipt1-, sur1-, skn1- and erg3-deletion
mutants, are miconazole resistant, suggesting 
an involvement of membrane rafts in its mode 
of action. This is supported by the 
antagonizing effect of membrane raft 
disturbing compounds on miconazole 
antifungal activity as well as on the 
miconazole-induced actin cytoskeleton 
stabilization and ROS accumulation. These 
antagonizing effects point to a primary role 
for membrane rafts in miconazole antifungal 
activity. We further show that this primary 
role of membrane rafts on miconazole action 
consists of mediating intracellular 
accumulation of miconazole in yeast cells. 
The class of azole antimycotics 
constitutes the largest group of synthetic 
antifungal therapeutics currently in clinical use. 
The generally accepted mode of antifungal 
action of azoles is the inhibition of ergosterol 
biosynthesis arising from a multimechanistic 
process initiated by the inhibition of two 
cytochrome P450 enzymes involved in 
ergosterol biosynthesis, namely the P450 
enzyme that catalyzes the lanosterol 14Į-
demethylation step and the P450 enzyme that 
catalyzes ¨22 desaturation (1). Azole treatment 
results in predominance of 14Į-methylated 
sterols and inhibition of subsequent reactions of 
the ergosterol biosynthesis pathway (1). Apart 
from inhibition of ergosterol biosynthesis, 
miconazole induces accumulation of reactive 
oxygen species (ROS) in susceptible fungi, 
leading to fungal cell death (2,3). Moreover, we 
could demonstrate that miconazole induces actin 
stabilization prior to this ROS accumulation (4). 
These data point to an ancillary mode of action 
for this azole, as was already suggested in the 
1970s (5). 
In order to obtain further mechanistic 
insight in the mode of antifungal action of 
miconazole, we screened in the present study the 
complete haploid collection of 4853 
Saccharomyces cerevisiae deletion mutants, 
individually deleted for non-essential genes, for 
resistance towards miconazole on solid medium. 
Using this strategy, we could demonstrate that S. 
cerevisiae mutants affected in sphingolipid and 
ergosterol biosynthesis are resistant to 
miconazole, suggesting a possible involvement 
of membrane rafts in the mode of antifungal 
action of miconazole. These rafts are membrane 
patches that are enriched in sphingolipids and 
ergosterol and that are thought to 
compartmentalize the plasma membrane and to 
have an important role in cell signaling (6). We 
investigated the effect of membrane raft 
disturbing compounds on (i) miconazole 
antifungal activity, (ii) the miconazole-induced 
actin cytoskeleton stabilization and (iii) the 
miconazole-induced ROS accumulation. 
Furthermore, using HPLC analysis we 
investigated the effect of membrane raft 
disruption on intracellular accumulation of 
miconazole in yeast cells. 
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Experimental procedures 
Materials, yeast strains, plasmids and growth 
media- Miconazole and methyl-ȕ-cyclodextrin 
(MȕCD) were purchased from Sigma-Aldrich. 
Edelfosine was a kind gift from Prof. 
Christopher McMaster (Atlantic Research 
Centre, Halifax, Canada). Acetonitrile was 
purchased from Fisher Scientific (Leicestershire, 
UK). Yeast strains used are Saccharomyces 
cerevisiae strain BY4741 (wild-type, WT) and 
the BY4741-derived deletion mutant library 
(Invitrogen, Carlsbad, Ca). These yeast strains 
were cultivated in Yeast Peptone Dextrose 
(YPD) (1% yeast extract, 2% peptone, 2% 
glucose). The plasmid encoding GFP-tagged 
Pma1p was a kind gift of Prof. Annick Breton 
(7). Yeast strains transformed with this plasmid 
were cultured in SC-ura (0.8 g/l CSM-ura, 
complete amino acid supplement mixture minus 
uracil, Bio 101 Systems; 6.5 g/l YNB, yeast 
nitrogen base; 20 g/l glucose).
Screening of a yeast deletion mutant library for 
miconazole resistance- The individual yeast 
deletion mutants were grown in 96 well 
microtiterplates containing 100 L YPD. After 
48h incubation at 30°C, the individual deletion 
mutants were spotted on YPD agar plates 
containing 10 g/mL miconazole using a 96-pin 
replicator for identification of miconazole 
resistant yeast deletion mutants. After 48 to 72h 
incubation at 30°C, plates were scored and 
resistant mutants were identified. Miconazole 
resistant mutants were reassessed using the assay 
described below. 
Quantification of miconazole resistance of the 
selected yeast mutant- Five-l samples of 
fivefold serial dilutions of each yeast cell culture 
(grown to stationary phase in YPD in 
microtiterplates) were spotted on YPD plates 
containing 0 or 10 g/ml miconazole. Growth 
was assessed after 48h of incubation at 30°C. 
Analysis of membrane raft disturbing activity of 
edelfosine and miconazole- Membrane rafts 
were monitored using Pma1p as a marker protein 
(8) via Western blotting and fluorescence 
microscopy. To this end, membrane rafts were 
isolated according to a reported isolation method 
(8-13). Briefly, a logarithmically growing S. 
cerevisiae culture in YPD (OD600 = 2.0) was 
incubated with miconazole (0 or 10 Pg/ml) or 
edelfosine (50 Pg/ml) for 3h. Ten OD600 units of 
cells were lysed with glass beads and samples 
were split into two fractions: a homogenate (H) 
and a second fraction that was incubated with 
1% Triton X-100 for 30 minutes on ice. The 
detergent-treated sample was centrifuged at 
100,000 g for 1 h to yield a detergent resistant 
pellet (P) and a soluble (S) fraction. Proteins 
were precipitated by TCA and analyzed by gel 
electrophoresis and immunoblotting using an 
antibody against Pma1p. Additionally, a 
logarithmically growing S. cerevisiae culture 
transformed with a plasmid containing GFP-
tagged Pma1p was incubated either with 0 g/ml 
miconazole, 10 g/ml miconazole or 50 g/ml 
edelfosine for 3h. In vivo localization of GFP-
tagged Pma1p was performed by fluorescence 
microscopy using a Zeiss Axioplan2 (Carl Zeiss, 
Oberkochen, Germany) equipped with an 
AxioCam charge-coupled device camera and 
AxioVision 3.1 software. At least 100 cells were 
monitored for each condition. Experiments were 
repeated at least three times and data are means 
of duplicate measurements. 
Influence of membrane raft disturbing agents on 
miconazole activity- A S. cerevisiae overnight 
culture in YPD was diluted to a final 
concentration of 106 cells/ml in phosphate 
buffered saline (PBS), whereafter various 
concentrations of miconazole and edelfosine or 
MȕCD were added. After 4.5h of incubation at 
30°C, viability of the yeast culture was assessed 
by counting the number of colony forming units 
(CFUs) on YPD agar plates after 24h of 
incubation. Percentage survival is calculated as 
the ratio of the number of CFUs after treatment 
to the number of CFUs of the DMSO (control) 
treatment. Experiments were repeated at least 
three times and data are means of duplicate 
measurements. 
Fluorescence microscopy for visualization of 
actin cytoskeleton- Rhodamine-phalloidin 
staining was performed as previously described 
for F-actin (14,15). 
Influence of membrane raft disturbing agents on 
ROS accumulation induced by miconazole- A
logarithmically growing S. cerevisiae culture in 
YPD (OD600 = 2.0) was washed and resuspended 
in PBS in the presence of 0 or 10 g/ml 
miconazole in combination with various 
concentrations of edelfosine or MȕCD. After 1h 
of incubation at 30°C, 10 M 2’,7’-
dichlorofluorescin diacetate (DCFHDA; 
Molecular Probes, Inc. Eugene, Oreg) was added 
(2). The number of fluorescent yeast cells was 
determined using fluorescence microscopy 
(Nikon Optiphot microscope; excitation 485 nm, 
emission 525 nm). Experiments were repeated at 
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least three times and data are means of duplicate 
measurements. 
Quantitative analysis of intracellular 
accumulation of miconazole in yeast cells- An
overnight S. cerevisiae WT culture in YPD 
(approx. 108 cells/ml) was washed and 
resuspended in PBS (pH 7.4). 100 g/ml 
miconazole with or without 500 g/ml 
edelfosine or 20 mg/ml MȕCD was added to 500 
l of the above culture. To analyze the 
intracellular miconazole accumulation in ipt1-
deletion mutant cells, S. cerevisiae WT and ipt1-
deletion mutant cells were treated with 
miconazole but without addition of edelfosine. 
After 2.5h of incubation at 30°C while shaking, 
the supernatant of the yeast cultures was 
collected. The cell pellet was washed three times 
with PBS, whereafter 300 l 70% 
acetonitrile/30% PBS was added. The cells were 
lysed using a Phastprep (BIO101/Savant, 
Toronto) reciprocal shaker and the lysate 
clarified by centrifugation (5 min at 3000 rpm). 
Miconazole concentration in both supernatant 
and cell lysates was determined using HPLC, 
based on a miconazole standard series ranging 
from 10 to 100 g/ml. The HPLC system 
consisted of a LaChrom® L-7100 HPLC pump, a 
UV detector model L-7420 set at 260 nm, an L-
7200 programmable autosampler and an 
Interface D-7000 (all Hitachi, Tokyo, Japan). 
Twenty l samples were injected in duplo. UV 
signals were monitored and peaks were 
integrated using the D-7000 HSM software 
(Hitachi). The separation of miconazole was 
performed on a SunFire C18 3.5 m (4.6 x 100 
mm) column (Waters, Milford,MA) 
(equilibrated with acetonitrile/water 70/30 
(V/V)). The column was eluted in an isocratic 
way at 1.0 ml/min. Experiments were repeated at 
least three times and data are means of duplicate 
measurements. 
Statistical analysis- Statistical analysis was 
performed using unpaired t test. 
RESULTS 
 Identification of miconazole resistant 
yeast deletion mutants. To obtain more 
mechanistic insight in the antifungal mode of 
action of miconazole, we started our study by 
screening a Saccharomyces cerevisiae deletion 
mutant library for resistance towards miconazole 
by replica-plating on miconazole-containing 
YPD agar plates. This deletion mutant library 
consists of single-gene knockouts in the S. 
cerevisiae BY4741 parental strain (WT) and 
covers all 4835 open reading frames (ORFs) 
encoding non-essential proteins.  
First, we determined the minimal 
inhibitory concentration (MIC) of miconazole 
for the WT strain in YPD agar plates as 1 g/ml. 
Second, screening for miconazole-resistant 
deletion mutants was performed on YPD agar 
plates containing 10-fold the MIC, i.e. 10 g/ml 
miconazole. Using this genome-wide approach, 
12 deletion mutants with at least 10-fold 
increased resistance to miconazole were 
identified (Table 1). Two major functional gene 
groups could be identified: genes involved in (i) 
sphingolipid and ergosterol biosynthesis and (ii) 
mitochondrial function. Additionally, SIP3 and 
ADH1 were identified, encoding a transcription 
factor and an alcohol dehydrogenase, 
respectively. Moreover, ORFs encoding 
hypothetical proteins were also identified as 
miconazole sensitivity genes. Resistance of the 
individual mutants was confirmed and quantified 
using yeast dilutions on agar with and without 
miconazole (Fig. 1). 
Since miconazole induces ROS 
accumulation in susceptible fungi (2-4), it is not 
surprising that we identified yeast deletion 
mutants affected in mitochondrial function to be 
resistant to miconazole. Hence, in this 
manuscript, we will focus on the class of 
miconazole sensitivity genes involved in 
sphingolipid and ergosterol biosynthesis, i.e. 
IPT1, SKN1, SUR1 and ERG3. Only yeast 
mutants displaying at least 10-fold increased 
miconazole resistance in agar were selected. 
Other mutants in genes in volved in ergosterol or 
sphingolipid biosynthesis seem characterized by 
less pronounced miconazole resistance. 
Role of membrane rafts in miconazole 
antifungal activity. In fungal membranes, 
sphingolipids and ergosterol are preferentially 
located in specific domains, termed membrane 
rafts. Membrane rafts are thought to 
compartmentalize the plasma membrane and to 
have an important role in cell signaling (6). 
Since we found mutants affected in both 
sphingolipid and ergosterol biosynthesis to be 
miconazole resistant, we hypothesized that 
membrane rafts play an important role in 
miconazole antifungal action. To test this 
hypothesis, we treated S. cerevisiae WT with 
membrane raft disturbing agents, namely 
edelfosine and methyl-ȕ-cyclodextrin (MȕCD) 
in order to phenocopy mutants affected in proper 
membrane raft composition, and analyzed 
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whether these agents can modulate miconazole 
antifungal activity. Edelfosine (1-O-octadecyl-2-
O-methyl-rac-glycero-3-phosphocholine) is an 
anti-cancer lysophospholipid that interferes with 
sphingolipid metabolism and alters the 
organization and composition of lipid rafts (16). 
MȕCD is a sterol-sequestering agent that is 
commonly used to disturb membrane rafts 
(17,18). Administration of 10 g/ml miconazole 
to a 1/100 diluted overnight culture of S. 
cerevisiae WT resulted in less than 0.1% 
survival, whereas simultaneous addition of 50 or 
100 g/ml edelfosine and miconazole resulted in 
increased survival of the yeast culture (72.6 ± 
9.5% or 99.0 ± 4.5 % survival, respectively, 
p<0.01). Similar results were obtained with 
MȕCD: simultaneous addition of 1.2 or 2.5 
mg/ml MȕCD and miconazole resulted in 
increased survival of the yeast culture (10.9 ± 
2.5% or 99.0 ± 4.5% survival, respectively, 
p<0.025). Apparently, disruption of membrane 
rafts leads to a decrease in miconazole antifungal 
activity and hence, antagonizes miconazole 
action. In order to analyze whether miconazole 
itself disrupts membrane rafts, we used Pma1p 
as a marker to monitor lipid rafts (8). 
Fractionation revealed normal enrichment of 
Pma1p in the raft fraction of control- and 
miconazole-treated WT cells (Fig. 2A), 
indicating that miconazole does not disrupt 
membrane rafts. In cells treated with edelfosine, 
Pma1p is present in the soluble fraction, 
indicating that under these conditions edelfosine 
indeed disrupts the association of Pma1p with 
membrane rafts (Fig. 2A). This is corroborated 
by fluorescence microscopy analysis, which 
reveals normal localization of Pma1p in the 
plasma membrane upon miconazole treatment 
and mislocalization of Pma1p in punctuate 
structures upon edelfosine treatment (Fig. 2B & 
Table 2). Non-raft associated Pma1p is known to 
be endocytosed from the plasma membrane and 
degraded by targeting to the vacuole (8-11). 
These results show that miconazole itself does 
not disrupt membrane rafts. 
Role for membrane rafts in miconazole 
induced phenotypes. Since miconazole induces 
stabilization of the actin cytoskeleton prior to 
induction of ROS in yeast cells (4), we analyzed 
whether disruption of membrane rafts affects 
these phenotypes. To this end, we treated a 
logarithmically growing S. cerevisiae culture 
with 10 g/ml miconazole in the presence of 
membrane raft disrupting agents and analyzed 
induction of actin cytoskeleton stabilization and 
of ROS accumulation. First, miconazole (0 or 10 
g/ml) with or without edelfosine (100 g/ml) or 
MȕCD (2.5 mg/ml) was added to S. cerevisiae
cells. Samples were taken after 4h incubation at 
30°C to determine the effect of membrane raft 
disruption on actin cytoskeleton stabilization 
induced by miconazole. A normal organization 
of cortical actin patches and polarized actin 
cables was clearly observed in untreated cells or 
in cells treated with edelfosine or MȕCD (Fig. 
3). Addition of 10 g/ml miconazole resulted in 
aggregation of F-actin as was previously 
described (4). Combined treatment of the yeast 
cells with miconazole and edelfosine or MȕCD
resulted in alleviation of the miconazole-induced 
F-actin aggregation. These results demonstrate 
that disruption of membrane rafts antagonizes 
the aggregation of F-actin induced by 
miconazole. 
Second, treatment of S. cerevisiae cells 
with 10 g/ml miconazole resulted in 26.7 ± 
2.4% ROS positive cells, whereas combined 
treatment of the yeast cells with miconazole and 
edelfosine or MȕCD resulted in a decrease in 
ROS-positive cells (namely 8.1 ± 1.1% or 7.2 ± 
1.0% ROS positive cells upon coincubation with 
50 and 100 g/ml edelfosine, respectively, 
p<0.01; and 8.3 ± 1.8% or 9.0 ± 2.4% ROS 
positive cells upon coincubation with 1.2 or 2.5 
mg/ml MȕCD, respectively, p<0.025). The 
percentage of ROS positive cells of a yeast 
culture upon control treatment (i.e. DMSO 
control) was 4.7 ± 1.9%. These data indicate that 
addition of either edelfosine or MȕCD
antagonizes miconazole-induced ROS 
accumulation in S. cerevisiae. Hence, we could 
demonstrate that disruption of membrane rafts 
via edelfosine or MȕCD antagonizes both the 
actin cytoskeleton stabilization and endogenous 
ROS accumulation induced by miconazole. 
Effect of membrane raft disruption on 
intracellular accumulation of miconazole in 
yeast cells. Based on all data, it is clear that 
membrane rafts play an important primary role 
in the mode of antifungal action of miconazole. 
Therefore, we focused on a putative involvement 
of membrane rafts in intracellular accumulation 
of miconazole and analysed miconazole 
accumulation in yeast cells in the presence and 
absence of edelfosine or MȕCD. To this end, we 
treated a non-diluted overnight culture of S. 
cerevisiae WT in YPD with 100 g/ml 
miconazole with or without 500 g/ml 
edelfosine. After 2.5h of incubation, we 
determined the concentration of miconazole in 
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the cells and in the corresponding supernatant 
via HPLC analysis. Treatment of the cells with 
miconazole resulted in intracellular 
accumulation of 97.4 ± 1.5% miconazole, 
whereas 2.6 ± 1.5% miconazole was left in the 
corresponding supernatant of the treated cells. 
Coincubation of the culture with miconazole and 
edelfosine resulted in two-fold reduced 
intracellular accumulation of miconazole, 
namely 55.1 ± 5.7% intracellular miconazole 
and 44.9 ± 2.3% miconazole remaining in the 
supernatant (p<0.01). The corresponding 
survival percentages using these specific 
experimental conditions (increased inoculum 
and increased concentrations of miconazole and 
edelfosine) were 1.3% survival for miconazole-
treated culture versus 40.3% survival for 
miconazole and edelfosine-treated culture, 
pointing to a correlation between intracellular 
miconazole accumulation and its fungicidal 
activity. Similar results were obtained with 
MȕCD: combined treatment of the yeast cells 
with 100 g/ml miconazole and 20 mg/ml 
MȕCD resulted in two-fold reduced intracellular 
accumulation of miconazole, namely 54.3 ± 
0.7% intracellular miconazole and 45.7 ± 0.7% 
miconazole remaining in the supernatant 
(p<0.001). In summary, these results document 
the essential role for membrane rafts in 
intracellular accumulation and killing potential 
of miconazole. 
Since membrane rafts are patches that 
are enriched in sphingolipids and ergosterol, we 
further analyzed whether the reduced 
miconazole susceptibility of the miconazole-
resistant deletion mutants can be explained by a 
reduced intracellular miconazole accumulation. 
To this end, we treated non-diluted overnight 
cultures of S. cerevisiae WT and the ipt1-
deletion mutant with 100 g/ml miconazole. 
Treatment of the S. cerevisiae WT cells with 
miconazole resulted in 96.0 ± 1.2% intracellular 
miconazole accumulation. Treatment of the ipt1-
deletion mutant cells with miconazole resulted in 
only 67.0 ± 1.8% intracellular miconazole 
accumulation (p<0.01). This reduced 
accumulation in the ipt1-deletion mutant can 
explain its reduced sensitivity to miconazole 
treatment. 
DISCUSSION 
To obtain more mechanistic insight in 
the mode of antifungal action of miconazole, we 
screened the complete set of haploid deletion 
mutants of S. cerevisiae for increased resistance 
to miconazole in agar. As such, we identified 12 
miconazole sensitivity genes, which upon 
deletion, result in at least 10-fold increased 
resistance to miconazole. In this study, we 
focused on the functional group of miconazole 
sensitivity genes implicated in sphingolipid and 
ergosterol biosynthesis, represented by IPT1,
SKN1, SUR1 and ERG3. The role of ERG3 in 
azole resistance was already demonstrated since 
treatment of yeast with azoles results in the 
accumulation of 14Į-methylated sterols and 14Į-
methylergosta-8,24(28)-dein-3,6-diol (19,20). 
Formation of the latter sterol metabolite is 
thought to be catalyzed by ¨-5,6-desaturase 
(encoded by ERG3). Hence, inactivation of 
ERG3 can suppress toxicity and therefore cause 
azole resistance (19,20). Additionally, we found 
various mutants affected in sphingolipid 
biosynthesis to be miconazole resistant, 
suggesting a possible role for membrane rafts in 
miconazole antifungal action. Sphingolipids and 
ergosterol are enriched in membrane domains, 
termed membrane rafts. Membrane rafts are 
thought to compartmentalize the plasma 
membrane and to have an important role in cell 
signaling (6). We demonstrated that disruption 
of these rafts, by treatment with edelfosine or 
MȕCD, interferes with miconazole antifungal 
action, as well as with miconazole-induced 
stabilization of actin cytoskeleton and ROS 
accumulation. These data point to an important 
primary role for membrane rafts in miconazole 
antifungal action. Using HPLC analysis, we 
further demonstrated that coincubation of 
miconazole and either lipid raft disturbing agent 
resulted in reduced intracellular accumulation of 
miconazole in yeast cells.  
In conclusion, administration of agents 
that disturb lipid rafts in the plasma membrane, 
either by affecting sphingolipid biosynthesis or 
ergosterol sequestration (i.e. edelfosine or 
MȕCD, respectively), abolish the antifungal 
action and accumulation of miconazole. Whether 
the reduced intracellular accumulation of 
miconazole upon treatment of yeast cells with 
membrane-disturbing compounds is caused by a 
reduced uptake in yeast cells or by increased 
efflux remains to be determined. Moreover, the 
miconazole resistant ipt1-deletion mutant 
showed reduced intracellular miconazole 
accumulation, correlating intracellular 
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accumulation of miconazole with yeast cell 
death. 
A general role for plasma membrane 
(phospho)lipid and sterol composition in azole 
accumulation is postulated (21,22). In a study 
tracking the development of low-level 
fluconazole resistance in C. albicans, a gradual 
increase in membrane fluidity of fluconazole-
adapted strains was demonstrated whereas the 
phospholipid composition of the adapted strains 
was not significantly altered (21). However, 
ergosterol content was reduced whereas 
sphingolipid content was higher in resistant than 
in susceptible isolates. Hence, that study 
demonstrates that altering the ratio of ergosterol 
to sphingolipid content influences susceptibility 
to fluconazole. Moreover, Löffler and co-
workers compared the plasma membrane 
composition of five fluconazole-resistant C.
albicans isolates to that of three fluconazole-
sensitive ones (22). They demonstrated that one 
resistant C. albicans isolate had a decreased 
amount of ergosterol and a lower 
phosphatidylcholine:phosphatidyl-ethanolamine 
ratio in the plasma membrane. They postulated 
that these changes in plasma membrane lipid and 
sterol composition could be responsible for an 
altered uptake of fluconazole and hence for a 
reduced intracellular fluconazole accumulation. 
Whether membrane rafts are involved in 
intracellular accumulation of azoles in general 
remains to be determined. 
To our knowledge, this is the first report 
describing a role for a specific membrane 
compartment in intracellular accumulation of 
miconazole. Since membrane rafts have been 
suggested to be involved in endocytosis (23), it 
remains to be determined whether miconazole is 
taken up in S. cerevisiae cells by endocytosis. If 
so, our observed reduction of miconazole 
accumulation in yeast with disturbed membrane 
rafts could be explained by a reduced uptake of 
the drug. 
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FIGURE LEGENDS 
Fig. 1. Saccharomyces cerevisiae deletion mutants which are miconazole resistant. Five L
samples of fivefold serial dilutions of each yeast culture (rows) were spotted on YPD plates 
containing 0 g/ml miconazole (left pane) and 10 g/ml miconazole (right pane). Plates were 
incubated at 30°C during 48h. 
Fig. 2. Effect of edelfosine and miconazole on membrane rafts in S. cerevisiae WT. A 
logarithmically growing S. cerevisiae WT culture in YPD was incubated with either 0 g/ml 
miconazole, 10 g/ml miconazole or 50 g/ml edelfosine for 3h at 30°C. A. Raft association of 
Pma1p was examined by detergent extraction in following fractions: homogenate (H), detergent 
resistant pellet (P) and soluble (S) fraction. Proteins were precipitated by TCA and analyzed by gel 
electrophoresis and immunoblotting using an antibody against Pma1p. B. Pma1p-GFP localization 
was analyzed by fluorescence microscopy. Bar, 5m.  
Fig. 3. Lipid raft disruption affects miconazole-induced stabilization of actin cytoskeleton. A 
logarithmically growing S. cerevisiae WT culture in YPD was diluted in PBS, treated with 0 or 10 
g/ml miconazole with or without 100 g/ml edelfosine or 2.5 mg/ml MȕCD. After 4h incubation at 
30°C, cells were fixed and stained with rhodamine-phalloidin to determine organization of F-actin 
structures. Bar, 5 m. 
7
ht
tp
://
do
c.
re
ro
.c
h
Table 1. Genes that result in miconazole resistance upon deletion in S. cerevisiae
Gene ORF Description of gene product  
(i) ergosterol and sphingolipid biosynthesis
ERG3 YLR056W C-5 sterol desaturase, catalyzes the introduction of a C-5(6) double bind 
into episterol, a precursor in ergosterol biosynthesis 
SKN1 YGR143W Protein involved in sphingolipid biosynthesis 
IPT1 YDR072C Inositolphosphotransferase 1, involved in synthesis of mannosyldi-
inositolphosphorylceramide (M(IP)2C)
SUR1 YPL057C Probable catalytic subunit of mannosylinositolphosphorylceramide 
(MIPC) synthase 
(ii) mitochondrial function 
PTH1 YHR189W One of two mitochondrially-localized peptidyl-tRNA hydrolases 
MRPL23 YOR150W Mitochondrial ribosomal protein of the large subunit 
 YDR114C Hypothetical protein; deletion mutant is respiratory deficient 
(iii) gene expression 
SIP3 YNL257C Protein that activates transcription through interaction with DNA-bound 
Snf1p, potential Cdc28p substrate 
(iv) varia 
ADH1 YOL086C Alcohol dehydrogenase 
 YOR292C Hypothetical protein 
 YDR068W Hypothetical protein 
 YPL056C Hypothetical protein 
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Table 2. Percentage of cells with Pma1p-GFP localized intracellularly or at the cell perimeter. 
treatment Cells (%)a
 Pma1-GFP internalized Pma1-GFP not internalized 
DMSO 2.7±0.5 97.3±0.5 
miconazole 2.4±0.3 97.6±0.3 
edelfosine 70.5±3.5 29.5±3.5 
aPercentage of cells with the specified phenotype was determined as the ratio of the cells with the 
specified phenotype, as visualised by fluorescence microscopy, to the total number of cells (n>100). 
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